YN001 Phase 2b Trial for Coronary Atherosclerosis
Summary
ClinicalTrials.gov registered a new Phase 2b clinical trial (NCT07521007) for YN001, an investigational product being evaluated for treatment of coronary atherosclerosis. The trial is sponsored by YN and will enroll patients to assess efficacy and safety endpoints.
What changed
ClinicalTrials.gov added a new trial registration for YN001 Phase 2b investigating coronary atherosclerosis treatment. The registry entry includes trial identifiers, phase classification, study objectives, and sponsor information.
Pharmaceutical sponsors conducting cardiovascular drug development and clinical investigators specializing in cardiology should monitor this trial for competitive intelligence and potential collaboration or referral opportunities.
What to do next
- Monitor ClinicalTrials.gov for protocol updates
- Review enrollment criteria for potential patient referrals
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.